In addition to being a tumor burden marker, AFP reshapes the immunosuppressive microenvironment through mechanisms such as inducing immune tolerance, inhibiting dendritic cell antigen presentation, promoting Treg cell expansion, and upregulating PD-L1 expression, thereby weakening the response to immunotherapy (37). The gene discussed is CD274; the disease is neoplasm.